About this item:
1,014 Views | 782 Downloads
Author Notes:
J-LV has no conflicts of interest related to this article.
JW is a member of the Advisory Boards and an invited speaker for Baxter, Danone, Fresenius-Kabi, Grifols, and Nestlé.
Subjects:
- Health Sciences, General
- Health Sciences, Health Care Management
- Health Sciences, Medicine and Surgery
Research Funding:
This report was sponsored by an unrestricted educational grant from Grifols SA (Barcelona, Spain). Grifols had no input into the contents of the text or the decision to publish.
JAR reports patents owned by the University of British Columbia that are related to the genetics of sepsis and its treatment; the University of British Columbia has also submitted a patent related to the use of vasopressin in septic shock. JAR is an inventor on these patents. JAR also reports receiving consulting fees from Ferring Pharmaceuticals (which manufactures vasopressin and is developing selepressin), Grifols (which sells albumin), Trius Pharmaceuticals (which is developing antibiotics), and Sirius Genomics Inc.; and reports having received grant support from Sirius Genomics, Ferring Pharmaceuticals, and Astra Zeneca that is provided to and administered by the University of British Columbia.
MJ has held lectures for B. Braun, Fresenius Kabi, Serumwerk Bernburg, Baxter and Grifols; has received unrestricted research grants from Fresenius Kabi, CSL Behring, Serumwerk Bernburg and Grifols; and is a member of the Grifols AAB.
GM serves on advisory boards for Grifols and CSL Behring, and his institution has received research grant support from Baxter Healthcare.
BG has received honoraria for lectures from Fresenius Kabi and LFB, and he is on the advisory board of Grifols and Fresenius Kabi.
RFR has received honoraria for lectures from Pfizer, Astellas and Grupo Ferrer, and is on the Advisory boards of Grifols, Bellco and Grupo Ferrer.
SAM has received speaker's honoraria from Fresenius Kabi. LG is on the Advisory board of Grifols and has received speaker’s honoraria from KCI, B. Braun, Baxter, Grifols, and Kedrion.
Keywords:
- Science & Technology
- Life Sciences & Biomedicine
- Critical Care Medicine
- General & Internal Medicine
- TRAUMATIC BRAIN-INJURY
- HUMAN SERUM-ALBUMIN
- SPONTANEOUS BACTERIAL PERITONITIS
- CORONARY-ARTERY-BYPASS
- INTENSIVE-CARE-UNIT
- ACUTE KIDNEY INJURY
- ACUTE LUNG INJURY
- SEVERE SEPSIS
- CRITICALLY-ILL
- SEPTIC SHOCK
Albumin administration in the acutely ill: what is new and where next?
Abstract:
Copyright information:
© 2014 Vincent et al.; licensee BioMed Central Ltd.
